Federal Register #DEA-1666

This opportunity involves the Drug Enforcement Administration (DEA) reviewing an application from SpecGx LLC to become a bulk manufacturer of controlled substances. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - OEM/Vendor: - SpecGx LLC (applicant and intended manufacturer) - Products/Services Requested: - Bulk manufacture of a wide range of Schedule I and II controlled substances - Includes: Gamma Hydroxybutyric Acid, synthetic Tetrahydrocannabinols, Psilocybin, Codeine-N-oxide, Dihydromorphine, Difenoxin, Morphine-N-oxide, Normorphine, Alphamethadol, Betamethadol, Norlevorphanol, Acetyl Fentanyl, Butyryl Fentanyl, Fentanyl-related compounds, Amphetamine, Methamphetamine, Lisdexamfetamine, Methylphenidate, Nabilone, ANPP, Phenylacetone, Codeine, Dihydrocodeine, Oxycodone, Hydromorphone, Diphenoxylate, Ecgonine, Hydrocodone, Levorphanol, Isomethadone, Meperidine, Meperidine intermediates, Methadone, Methadone intermediate, Dextropropoxyphene (bulk), Morphine, Oripavine, Thebaine, Opium tincture, Opium (powdered), Oxymorphone, Noroxymorphone, Alfentanil, Remifentanil, Sufentanil, Tapentadol, Fentanyl - No specific quantities or part numbers provided - Unique/Notable Requirements: - Only synthetic manufacture is planned for Tetrahydrocannabinols - Substances will be manufactured for both commercial sale and internal use to produce non-controlled substances - DEA is accepting public comments, objections, and hearing requests regarding this application - Place of Performance: - SpecGx LLC facility in Saint Louis, Missouri - DEA as the contracting/oversight office

SpecGx LLC has applied to be registered as a bulk manufacturer of various basic classes of controlled substances, including Schedule I and II drugs such as Gamma Hydroxybutyric Acid, Tetrahydrocannabinols, Psilocybin, Fentanyl, Methamphetamine, and others. The company plans to manufacture these substances for sale to customers and for internal use to produce non-controlled substances, with synthetic manufacture planned for Tetrahydrocannabinols. Interested parties may submit comments or objections and request hearings by May 26, 2026.